The world of OxPL
@OxPL_apoB has expanded to many areas beyond Lp(a). Inhibiting OxPL with our E06 antibody discovered
@UCSanDiego @UCSDCardiology in various models improves aortic stenosis, ischemia/reperfusion injury, MASH, metabolic disorders CNS DZ, bone metabolism, arthritis/joint disease, pain syndromes, pulmonary fibrosis, and now... asthma. Congrats to Andre Halyako and
@AHRavandi for the great study. Why such broad effects? Because anywhere there is oxidation, it begets inflammation, and E06 attenuates the pro-inflammatory effects. It's time to get it to the clinic!